IP Library › Granted Patent US 7,179,605
Granted Patent B2
US 7,179,605 · App. 09/993,289 · Granted Feb 20, 2007

Fibronectin precursor biopolymer markers indicative of alzheimer's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,605
App. No.
09/993,289
Granted
Feb 20, 2007
Kind
B2
Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

Claims (13)

1. An isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4.

2. A method for determining the presence of an isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4 comprising:

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample to elucidate peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

(c) confirming the presence of said isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 in said sample displaying a peak profile consisting of 1356.65 daltons for SEQ ID NO:1, 1625.84 daltons for SEQ ID NO:2, 1818.97 daltons for SEQ ID NO:3 and 1629.8713 daltons for SEQ ID NO:4 in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4 is indicative of a link to Alzheimer's disease.

3. The method of claim 2 , wherein said sample is an unfractionated body fluid or a tissue sample.

4. The method of claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

5. The method of claim 2 , wherein said mass spectrometric analysis is selected from the group of mass spectrometry procedures consisting of Surface Enhanced Laser Desorption Ionization (SELDI) Matrix-Assisted Laser Desorption/Ionization guadropole guadropole time-of-flight (MALDI Oq TOF), multiple sequential mass spectrometry (MS/MS), sequential time-of-flight (TOF-TOF), electrospray ionization quadropole time-of-flight (ESI-O-TOF) and ION-TRAP.

6. The method of claim 2 , wherein said patient is a human.

7. A kit for determining the presence of an isolated biopolymer marker consisting of SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4 comprising: (a) a peptide selected from the group consisting of SEQ ID NO:1; or SEQ ID NO:2, or SEQ ID NO:3 or SEQ ID NO:4, and (b) an antibody that binds to said peptide in a sample from a patient.

8. The kit of claim 7 , wherein said antibody is immobilized on a solid support.

9. The kit of claim 7 , wherein said antibody is labeled.